Taiko Pharmaceutical Co.,Ltd. (TYO:4574)

Market Cap	14.87B -7.7%
Revenue (ttm)	6.40B +1.7%
Net Income	923.00M +2.8%
EPS	18.37 +2.7%
Shares Out	50.25M
PE Ratio	16.11
Forward PE	22.87
Dividend	3.50 (1.22%)
Ex-Dividend Date	Dec 29, 2025

Volume	194,100
Average Volume	198,970
Open	297.00
Previous Close	286.00
Day's Range	295.00 - 302.00
52-Week Range	228.00 - 444.00
Beta	0.31
RSI	49.15
Earnings Date	Feb 13, 2026

About Taiko Pharmaceutical

Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines and quasi drugs in Japan and internationally. The company provides OTC medicines under the SEIROGAN, SEIROGAN TOI A and SEIROGAN Quick C, PISHUT OD Tablet brand names; and quasi-drugs under the RAPPA INTESTINAL REGULATOR BF brand names. It also offers sanitation control products under the Cleverin and Cleverin Generator LISPASS name. In addition, the company manufactures and sells wood vinegar-based products. The company exports its products. The company was i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 214
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4574

Financial Performance

In 2025, Taiko Pharmaceutical's revenue was 6.40 billion, an increase of 1.67% compared to the previous year's 6.29 billion. Earnings were 923.00 million, an increase of 2.78%.